Elliott Sigal's most recent trade in Alnylam Pharmaceuticals Inc was a trade of 1,558 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 8, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Alnylam Pharmaceuticals Inc | Elliott Sigal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 1,558 | 1,558 | - | - | Stock Option (right to buy) | |
Alnylam Pharmaceuticals Inc | Elliott Sigal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 775 | 775 (0%) | 0% | 0 | Common Stock | |
Vir Biotechnology Inc | Elliott Sigal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
Vir Biotechnology Inc | Elliott Sigal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 8,000 | 23,806 (0%) | 0% | 0 | Common Stock | |
Alnylam Pharmaceuticals Inc | Elliott Sigal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 5,228 | 5,228 | - | - | Stock Option (right to buy) | |
Vir Biotechnology Inc | Elliott Sigal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 12,054 | 12,054 | - | - | Stock Option (Right to Buy) | |
Vir Biotechnology Inc | Elliott Sigal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 6,027 | 15,806 (0%) | 0% | 0 | Common Stock | |
Alnylam Pharmaceuticals Inc | Elliott Sigal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 3,454 | 3,454 | - | - | Stock Option (right to buy) | |
Vir Biotechnology Inc | Elliott Sigal | Director | Purchase of securities on an exchange or from another person at price $ 22.73 per share. | 01 Mar 2023 | 2,500 | 10,000 (0%) | 0% | 22.7 | 56,816 | Common Stock |
Vir Biotechnology Inc | Elliott Sigal | Director | Purchase of securities on an exchange or from another person at price $ 24.96 per share. | 05 Jan 2023 | 2,500 | 7,500 (0%) | 0% | 25.0 | 62,396 | Common Stock |
Vir Biotechnology Inc | Elliott Sigal | Director | Purchase of securities on an exchange or from another person at price $ 25.60 per share. | 03 Jan 2023 | 2,500 | 2,500 (0%) | 0% | 25.6 | 63,993 | Common Stock |
Vir Biotechnology Inc | Elliott Sigal | Director | Purchase of securities on an exchange or from another person at price $ 25.25 per share. | 03 Jan 2023 | 2,500 | 5,000 (0%) | 0% | 25.3 | 63,136 | Common Stock |
Alnylam Pharmaceuticals Inc | Elliott Sigal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Aug 2022 | 4,456 | 4,456 | - | - | Stock Option (right to buy) | |
Vir Biotechnology Inc | Elliott Sigal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2022 | 12,810 | 12,810 | - | - | Stock Option (Right to Buy) | |
Vir Biotechnology Inc | Elliott Sigal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2022 | 6,405 | 9,779 (0%) | 0% | 0 | Common Stock | |
Vir Biotechnology Inc | Elliott Sigal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 6,748 | 6,748 | - | - | Stock Option (Right to Buy) | |
Vir Biotechnology Inc | Elliott Sigal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 3,374 | 3,374 (0%) | 0% | 0 | Common Stock | |
Vir Biotechnology Inc | Elliott Sigal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2020 | 28,394 | 28,394 | - | - | Stock Option (Right to Buy) |